Genentech disclosed head-to-head Phase 3 results showing its KRAS G12C inhibitor divarasib outperformed the approved KRAS G12C therapies in previously treated non-small-cell lung cancer. In the Krascendo-1 trial interim analysis, Roche said divarasib produced clinically meaningful improvements in overall survival and progression-free survival versus Lumakras (sotorasib) and Krazati (adagrasib), with no new safety signals. Roche said most treatment-related side effects were manageable and reversible, and it plans to submit the Phase 3 data to regulators and present details at an upcoming medical meeting. The FDA granted divarasib breakthrough therapy designation in 2022 and orphan drug designation in 2026 for KRAS G12C NSCLC. Separate coverage of the same head-to-head trial reinforced the competitive framing: Roche is targeting a new standard of care in second-line KRAS G12C NSCLC while continuing work in earlier-line settings such as Krascendo-2.